SAN DIEGO—(BUSINESS WIRE)—Aug. 5, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced the following senior
management appointments:
-
James A. Nash, Senior Vice President, Technology Development and
Operations
-
Ryan E. Brown, Vice President, Chief Compliance Officer
-
Fred W. Manak, Jr., Vice President, Access and Reimbursement
-
Bob Mischler, Vice President, Strategy and Business Development
“We are pleased to have these strong and experienced leaders join the
ACADIA team,” said Steve Davis, ACADIA’s Interim Chief Executive
Officer. “We look forward to their contributions as we prepare for our
New Drug Application submission and planned commercial launch of
NUPLAZID™ (pimavanserin) for Parkinson’s disease psychosis in the United
States, and as we seek to optimize the opportunities for pimavanserin in
other disease states.”
James A. Nash, Senior Vice President, Technology Development and
Operations
Mr. Nash joins ACADIA as Senior Vice President, Technology Development
and Operations. In this new role, he is responsible for pharmaceutical
development, manufacturing and GMP quality assurance. Mr. Nash brings
over 30 years of executive level experience in these key technical
functions. Prior to joining ACADIA, Mr. Nash served as Vice President,
Technology Development and Operations at ViroPharma Inc. from 2008 to
2014, where he established supply chain, quality assurance and process
development organizations in a rapidly growing specialty pharmaceutical
company and supported the successful launch of Cinryze® for
the treatment of hereditary angioedema. Previously, Mr. Nash served as
Executive Vice President, Technical Operations at Watson Laboratories,
Inc. where he led manufacturing, quality, and sourcing, managing seven
manufacturing locations worldwide, and significantly enhancing the
company’s operating efficiencies for delivering commercial products. He
also has held executive positions in manufacturing at Chiron
Corporation, Millennium Pharmaceuticals, Inc., and Searle
Pharmaceuticals, Inc. Mr. Nash received his Bachelor of Arts degree in
Zoology from the University of California, Berkeley and a Master of
Business Administration from Northwestern University.
Ryan E. Brown, Vice President, Chief Compliance Officer
Mr. Brown joins ACADIA as Vice President, Chief Compliance Officer. In
this new role, he is responsible for developing, implementing, and
managing the Company’s corporate compliance program to support the
planned commercialization of NUPLAZID and other future product
opportunities. Prior to joining ACADIA, he served as Vice President,
Chief Compliance Officer at Allergan, Inc. where he was responsible for
the strategic vision and management of the global corporate compliance
program and held other senior positions including General Counsel for
subsidiary SkinMedica and Chief of Staff to the Office of the President.
Mr. Brown received his Bachelor of Arts degree in Political Science from
Loyola Marymount University and his Juris Doctor degree from Harvard Law
School.
Fred W. Manak, Jr., Vice President, Access and Reimbursement
Mr. Manak joins ACADIA as Vice President, Access and Reimbursement. In
this new role, he is responsible for establishing ACADIA’s access and
reimbursement strategy to support the planned commercialization of
NUPLAZID and other future product opportunities. In addition, Mr. Manak
is responsible for managing the Company’s government affairs efforts.
Mr. Manak brings over 25 years of industry experience, primarily in
pharmaceutical access, reimbursement, pricing, and contracting.
Previously, Mr. Manak served as Vice President, Market Access at
InterMune, Inc. where he led the market access strategy for the launch
of Esbriet® in idiopathic pulmonary fibrosis. Prior to
joining InterMune, he served as Vice President, Reimbursement, Access
and Value at Onyx Pharmaceuticals, Inc., and as Executive Director,
Trade, Pricing and Contract Management at Amgen, Inc. Mr. Manak received
his Bachelor of Science in Chemistry from Muhlenberg College.
Bob Mischler, Vice President, Strategy and Business Development
Mr. Mischler joins ACADIA as Vice President, Strategy and Business
Development. In this new role, he is responsible for strategic planning
and business development initiatives. Prior to joining ACADIA, Mr.
Mischler served as Vice President, Scientific Affairs and Business
Development at Ardea Biosciences, a member of the AstraZeneca Group,
where he led the development and implementation of its lifecycle
management strategy for the global gout franchise. Previously, he served
as Vice President, Commercial Planning and Analytics at Ardea
Biosciences, where he was significantly involved in business development
and led commercial activities. Earlier in his career, he worked in
various roles focused on product and portfolio strategy at CovX Research
LLC, Pfizer Inc. and Eli Lilly and Company. Mr. Mischler received his
Bachelor of Science in Biologic Sciences from Indiana University and his
Master of Business Administration from the UCLA Anderson School of
Management.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in neurological and related central nervous system disorders. ACADIA has
a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for
which we have reported positive Phase III trial results in Parkinson’s
disease psychosis and which has the potential to be the first drug
approved in the United States for this disorder. Pimavanserin is also in
Phase II development for Alzheimer’s disease psychosis and has
successfully completed a Phase II trial in schizophrenia. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with Allergan, Inc. All product candidates are small
molecules that emanate from internal discoveries. ACADIA maintains a
website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials, the benefits to be derived from ACADIA’s
product candidates, in each case including NUPLAZID (pimavanserin), the
potential for NUPLAZID to be the first drug approved in the United
States for Parkinson’s disease psychosis, our ability to optimize
opportunities for pimavanserin, and the benefits of contributions from
our senior management appointments. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and
collaborations with others, and the fact that past results of clinical
trials may not be indicative of future trial results. For a discussion
of these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended December 31, 2014 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150805005543/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, Interim Chief
Executive Officer
Lisa Barthelemy, Director of Investor
Relations
858-558-2871